•Telix Pharmaceuticals announced that Part 1 of the ProstACT Global Phase 3 study for its therapeutic candidate TLX591-Tx has achieved its primary objectives.
•The study demonstrated an acceptable safety and tolerability profile with no new safety signals observed in the safety and dosimetry lead-in phase.
•The US Department of Transportation and FAA selected Archer's partners in Texas, Florida, and New York to participate in the eVTOL Integration Pilot Program (eIPP).
•The program marks a major step toward commercializing electric air taxis in the US, representing the first new aircraft category in nearly 80 years.
•Starboard Value LP, a significant stockholder in Lamb Weston Holdings Inc. (LW), announced it has delivered a letter to the Company's CEO and Board of Directors.
•Starboard Value is a well-known activist investor that typically seeks strategic or operational changes in its portfolio companies.
